635 related articles for article (PubMed ID: 29933862)
1. Cost effectiveness of decentralised care model for managing MDR-TB in India.
John D; Chatterjee P; Murthy S; Bhat R; Musa BM
Indian J Tuberc; 2018 Jul; 65(3):208-217. PubMed ID: 29933862
[TBL] [Abstract][Full Text] [Related]
2. Cost-optimization in the treatment of multidrug resistant tuberculosis in Nigeria.
Musa BM; John D; Habib AG; Kuznik A
Trop Med Int Health; 2016 Feb; 21(2):176-82. PubMed ID: 26610176
[TBL] [Abstract][Full Text] [Related]
3. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treating multidrug-resistant tuberculosis.
Resch SC; Salomon JA; Murray M; Weinstein MC
PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
6. Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia's implementation of universal health coverage.
Fuady A; Houweling TAJ; Mansyur M; Richardus JH
Infect Dis Poverty; 2018 Jan; 7(1):3. PubMed ID: 29325589
[TBL] [Abstract][Full Text] [Related]
7. Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India.
Mullerpattan JB; Udwadia ZZ; Banka RA; Ganatra SR; Udwadia ZF
Indian J Tuberc; 2019 Jan; 66(1):87-91. PubMed ID: 30797290
[TBL] [Abstract][Full Text] [Related]
8. Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa.
Schnippel K; Rosen S; Shearer K; Martinson N; Long L; Sanne I; Variava E
Trop Med Int Health; 2013 Jan; 18(1):109-16. PubMed ID: 23170876
[TBL] [Abstract][Full Text] [Related]
9. How affordable is TB care? Findings from a nationwide TB patient cost survey in Ghana.
Pedrazzoli D; Siroka A; Boccia D; Bonsu F; Nartey K; Houben R; Borghi J
Trop Med Int Health; 2018 Aug; 23(8):870-878. PubMed ID: 29851223
[TBL] [Abstract][Full Text] [Related]
10. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
11. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.
van den Hof S; Collins D; Hafidz F; Beyene D; Tursynbayeva A; Tiemersma E
BMC Infect Dis; 2016 Sep; 16(1):470. PubMed ID: 27595779
[TBL] [Abstract][Full Text] [Related]
12. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
13. Cost-consequence analysis of ambulatory clinic- and home-based multidrug-resistant tuberculosis management models in Eswatini.
Peresu E; De Graeve D; Heunis JC; Kigozi NG
PLoS One; 2024; 19(4):e0301507. PubMed ID: 38564589
[TBL] [Abstract][Full Text] [Related]
14. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa.
Loveday M; Wallengren K; Voce A; Margot B; Reddy T; Master I; Brust J; Chaiyachati K; Padayatchi N
Int J Tuberc Lung Dis; 2012 Feb; 16(2):209-15. PubMed ID: 22236922
[TBL] [Abstract][Full Text] [Related]
15. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
16. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
Pablos-Mendez A; Gowda DK; Frieden TR
Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of treating multidrug-resistant tuberculosis in treatment initiative centers and treatment follow-up centers in Ethiopia.
Alemayehu S; Yigezu A; Hailemariam D; Hailu A
PLoS One; 2020; 15(7):e0235820. PubMed ID: 32716915
[TBL] [Abstract][Full Text] [Related]
18. Cost of multi drug resistance tuberculosis in Germany.
Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
[TBL] [Abstract][Full Text] [Related]
19. Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India.
Rupani MP; Cattamanchi A; Shete PB; Vollmer WM; Basu S; Dave JD
Infect Dis Poverty; 2020 Oct; 9(1):144. PubMed ID: 33076969
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
